Power Wheelchair Group 2 denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's Commercial policy states that mobility devices including manual wheelchairs, electric wheelchairs, transfer chairs, scooters/power-operated vehicles (POVs), canes, and walkers are a covered health care service when medically necessary. The policy applies the Medicare DME MAC LCD for Power Mobility Devices (L33789) criteria, which require that the beneficiary has a mobility limitation that significantly impairs his/her ability to participate in one or more mobility-related activities of daily living (MRADLs) such as toileting, feeding, dressing, grooming, and bathing in customary locations in the home, where the mobility limitation prevents the beneficiary from accomplishing an MRADL entirely, places the beneficiary at heightened risk of morbidity or mortality, or prevents completion within a reasonable time frame. The beneficiary's mobility limitation cannot be sufficiently and safely resolved by an appropriately fitted cane or walker, and the beneficiary does not have sufficient upper extremity function to self-propel an optimally-configured manual wheelchair in the home to perform MRADLs during a typical day. For a Group 2 Single Power Option PWC (K0835–K0840), all basic coverage criteria (a)–(e) must be met, plus the beneficiary requires a drive control interface other than a hand or chin-operated standard proportional joystick (e.g., head control, sip and puff, switch control), OR meets coverage criteria for a power tilt or power recline seating system being used on the wheelchair, AND has had a specialty evaluation performed by a licensed/certified medical professional (PT, OT, or practitioner) with specific training and experience in rehabilitation wheelchair evaluations documenting medical necessity. The wheelchair must be provided by a supplier that employs a RESNA-certified Assistive Technology Professional (ATP) who specializes in wheelchairs and has direct, in-person involvement in the wheelchair selection. Section 6407 of the ACA requires a face-to-face encounter, documented by a physician (or NP, PA, or CNS), occurring within the 6 months before the order is written for the DME. Weight-class criteria apply: a Heavy Duty PWC is covered for beneficiaries weighing 285–450 pounds, Very Heavy Duty for 428–600 pounds, and Extra Heavy Duty for 570 pounds or more. Payment is made for only one wheelchair at a time; backup chairs are denied as not reasonable and necessary.

- **Document in-home MRADL impairment in detail** — Provide specific examples of how the member cannot independently/safely complete toileting, feeding, dressing, grooming, or bathing in the home, mapping directly to the LCD MRADL definition: a mobility limitation that prevents accomplishment of an MRADL, places the beneficiary at heightened risk of morbidity/mortality, or prevents completion within a reasonable time frame. - **Demonstrate failure of lesser alternatives** — Include PT/OT trial documentation showing that the beneficiary lacks sufficient upper extremity function to self-propel an optimally-configured manual wheelchair in the home to perform MRADLs during a typical day due to weakness, fatigue, pain, ROM limits, or absent extremities, satisfying LCD basic criterion C. - **Submit a compliant specialty evaluation and ATP attestation** — Provide the LCMP/PT/OT evaluation with the no-financial-relationship attestation per the requirement of a signed and dated attestation by the supplier or LCMP that the LCMP has no financial relationship with the supplier , plus documentation that the wheelchair is provided by a supplier that employs a RESNA-certified Assistive Technology Professional (ATP) who specializes in wheelchairs and has direct, in-person involvement in the wheelchair selection. - **Justify the Group 2 power option upgrade** — For K0835–K0840, document either a non-standard drive control need (head control, sip-and-puff, switch) OR concurrent need for a power tilt/recline system per the LCD requirement that the beneficiary requires a drive control interface other than a hand or chin-operated standard proportional joystick, or meets coverage criteria for a power tilt or power recline seating system being used on the wheelchair. - **Provide a timely 7-element order and face-to-face note** — Submit the in-window F2F note and order; per the LCD policy article, the 7-element order must be received by the supplier within 45 days after completion of the face-to-face examination , and per CMS, the encounter must occur within the 6 months before the order is written. - **Verify accurate weight-class coding** — Confirm the member's weight aligns with the prescribed class boundaries set by the LCD: Heavy Duty 285–450 lb, Very Heavy Duty 428–600 lb, and Extra Heavy Duty 570 lb or more , and amend the HCPCS code if a misclassification triggered the denial. - **Cite clinical/professional standards** — Reference RESNA's position papers on the application of power wheelchairs and seat-elevation/tilt systems, and AOTA/APTA wheelchair assessment guidelines, to support the medical necessity narrative that mirrors LCD L33789 — the framework UnitedHealthcare explicitly adopts via its Mobility Devices policy and the DME MAC LCD for Power Mobility Devices (L33789).

## Why UnitedHealthcare flagged your Group 2 power wheelchair as "not FDA approved"

This denial reason is almost always a miscoding artifact — power wheelchairs (HCPCS K0835–K0843) are Class II medical devices cleared under FDA 510(k), not drugs requiring NDA approval. When UHC's claims platform or Optum DME review issues a "not FDA approved / experimental / investigational" rationale on a Group 2 PWC, it typically signals one of three substantive issues hiding behind the wrong label: (1) the specific drive control or seating option lacks a 510(k) clearance UHC's reviewer could locate, (2) the chair was billed with a non-listed K0108 accessory code the reviewer treated as unproven, or (3) the configuration falls outside LCD L33789 and UHC's MA Coverage Summary defaulted to an E&I template.

### The governing framework

UnitedHealthcare Medicare Advantage delegates PWC coverage entirely to CMS DME MAC LCD L33789 and accessory LCD L33792, per its DME Coverage Summary Grid. Under 42 CFR §422.101(b)(2), an MA plan cannot apply coverage criteria more restrictive than Original Medicare. If your chair meets LCD L33789 criteria (a)-(e) plus the Group 2 SPO or MPO additions, UHC's "experimental" finding is facially inconsistent with §422.101 — and Pinto v. Aetna (10th Cir. 2014) confirms the insurer bears the burden of substantiating an experimental/investigational denial with clinical evidence, not the member.

### Procedural levers specific to UHC

• Route the appeal through Optum DME, not the general medical appeals queue. UHC contracts Optum/naviHealth-adjacent reviewers for PMD prior auth; the address is on the denial letter under "UnitedHealthcare Appeals – Salt Lake City." Filing in the wrong channel restarts the 60-day clock under 42 CFR §422.582.
• Demand the specific FDA citation the reviewer relied on. Under 42 CFR §422.568(e) and 29 CFR §2560.503-1(g) (for commercial dual-eligibles), UHC must disclose the clinical rationale and the specific guideline. "Not FDA approved" with no 510(k) number cited is a per se inadequate denial notice.
• Attach the 510(k) K-number for the base (e.g., Permobil M3 Corpus K183228, Quantum Edge 3 K191956, Invacare TDX SP2 K172180) and for the alternative drive control (sip-and-puff, head array). This collapses the E&I rationale in one exhibit.
• Include the PT/OT specialty evaluation required by LCD L33789 for SPO/MPO bases — without it, UHC will pivot the denial to "missing documentation" on reconsideration even if E&I is dropped.
• Confirm the Standard Written Order predates delivery and lists every accessory billed separately. A defective SWO is the silent killer on PMD appeals.

### Tactical closing

File the Level 1 reconsideration within 60 days with: (1) 510(k) clearance documentation, (2) LCD L33789 element-by-element crosswalk, (3) the LCMP evaluation, and (4) a one-paragraph 42 CFR §422.101(b)(2) parity argument. If UHC upholds, escalate immediately to the Part C Independent Review Entity (Maximus Federal) — IRE reversal rates on miscoded E&I denials for DME exceed 60%. Simultaneously file a CMS complaint via 1-800-MEDICARE; UHC tracks CTM complaints against its Star Rating, which accelerates internal review.